- Teleconference Scheduled for August 7, 2017, at 5:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the second quarter ended June 30, 2017 and provide a mid-year update on August 7, 2017, after the NASDAQ market closing.
Conference Call/Webcast Information
Interested parties may access the live audio webcast of the teleconference at 5:00 p.m. ET through the Investor and News page of CytomX’s website at http://ir.cytomx.com or by dialing 1-877-809-6037 and using the passcode 61956517. A replay will be available on the CytomX website or by dialing 1-855-859-2056 and using the passcode 61956517. The replay will be available from August 7, 2017, until August 14, 2017.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166 and CD71. The Company’s lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is being evaluated in a Phase 1/2 study as part of PROCLAIM (Probody Clinical Assessment In Man), an international umbrella clinical trial program that provides clinical trial sites with access to the Company’s novel therapies under one central protocol. A Phase 1/2 clinical trial for CX-2009, a first-in-class Probody drug conjugate, targeting the highly expressed tumor antigen, CD166, is also in progress under the PROCLAIM umbrella. In addition to its wholly owned programs, CytomX is collaborating with strategic partners, including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. BMS expects to advance its first collaboration product candidate, a Probody therapeutic targeting CTLA-4, into clinical studies in early 2018. CytomX, in collaboration with AbbVie, expects to advance the CD71-targeting Probody Drug Conjugate, CX-2029, into clinical studies in 2018. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact: Spectrum Christine Quern cquern@spectrumscience.com 202-587-2588 Investor Contact: Trout Group Pete Rahmer prahmer@troutgroup.com 646-378-2973
